German SME supplying immunological reagents to EU research consortia in clinical transplant immunology and veterinary vaccine development.
ImmunoTools GmbH is a German SME specialising in the production and supply of immunological reagents — most likely custom antibodies, cytokine products, and related biological tools used in research and diagnostics. Their participation in RETHRIM and Paragone as a supplier-partner suggests they provide the biological materials that larger research consortia depend on to run experiments, assays, and vaccine development workflows. Rather than leading scientific discovery themselves, they are an enabling partner: their value is in the quality, specificity, and reliability of the immunological tools they deliver to academic and industrial research teams. This positions them in the niche where manufacturing precision meets life-science research, serving both clinical immunology and veterinary vaccine pipelines.
Both RETHRIM and Paragone are immunology-intensive projects (GvHD therapy and parasite vaccines), and ImmunoTools' company name and SME profile strongly indicate they supply biological reagents to these consortia.
RETHRIM focused on restoring tissue regeneration in patients with visceral Graft versus Host Disease, a condition driven by dysregulated immune responses requiring specialised immunological tools.
Paragone targeted vaccine development against animal parasites, suggesting ImmunoTools can supply or develop immunological components for veterinary as well as human medicine applications.
In both projects ImmunoTools participated without coordinating, consistent with a specialist supplier role within multi-partner consortia.
Both H2020 projects began in 2015, which means there is no meaningful timeline split between an early and a later period — ImmunoTools entered H2020 simultaneously on two different fronts, one in clinical immunology and one in veterinary vaccines. Without keyword data or later-stage projects, it is not possible to trace a genuine evolution; the two parallel threads may reflect their product catalogue spanning both human and animal health rather than a strategic pivot. If they have not taken on further EU projects since 2015, this could indicate they treat EU research participation as occasional rather than a core activity.
With both projects launched in 2015 and no recorded activity beyond 2021, the trajectory is unclear — they may be selectively engaged in EU research as a reagent supplier rather than actively growing a project portfolio.
ImmunoTools has never coordinated a project and participates exclusively as a partner, consistent with a specialist supplier that joins consortia to provide specific materials or expertise rather than to lead scientific programmes. Across just two projects they accumulated 32 distinct consortium partners, suggesting they worked within large, multi-institution networks rather than tight bilateral arrangements. This breadth of exposure indicates they are comfortable operating inside complex consortia but are not a relationship-intensive hub — they contribute a defined deliverable and let others handle project management.
ImmunoTools has collaborated with 32 unique partners across 11 countries through only two projects, indicating they were embedded in large international consortia. Their reach spans most of Western and Central Europe, which is typical for RIA-funded health and food research networks.
ImmunoTools occupies a relatively rare niche as a small German company that bridges human clinical immunology and veterinary immunology within EU-funded research, suggesting their reagent portfolio is broad enough to serve both fields. Based in Friesoythe — a non-metropolitan location — they are likely a lean, specialist producer rather than a diversified biotech, which can mean faster, more personalised supply relationships than larger reagent houses. For a consortium needing a reliable, EU-experienced immunological tools supplier who will not compete for scientific leadership, they are a low-friction partner.
